Immunovant — Second Quarter 2026 Earnings Summary

Immunovant reported that its drug candidate IMVT-1402 at a 600 mg dose met the primary endpoint of ACR20 response at Week 28 in a Phase 2 trial for difficult-to-treat rheumatoid arthritis, showing a 92.5% response rate compared to 75.6% for placebo. The company plans to discuss the future of its registrational program for this indication with the FDA later in 2026 but expects to discontinue further development of IMVT-1402 in Sjögren's disease beyond its current Phase 2 trial. For the quarter ended September 30, 2026, the company reported a net loss of $97.2 million and held $722.3 million in cash and cash equivalents. Topline data for IMVT-1402 trials in Graves' disease and myasthenia gravis are anticipated in 2027, with data for chronic inflammatory demyelinating polyneuropathy expected in 2028.